Author

M. Van Loock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Buyck· 2 shared D. Bojkova· 2 shared D. Jochmans· 2 shared E. Van Damme· 2 shared J. Cinatl· 2 shared J. Neyts· 2 shared P. Leyssen· 2 shared S. Ciesek· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. Buyck

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Evolution of inflammation and immunity in a dengue virus 1 human infection model

A. T. Waickman, J. Q. Lu, H. Fang, M. Waldran, C. Gebo, J. R. Currier, L. Van Wesenbeeck, N. Verpoorten, O. Lenz, L. Tambuyzer, G. Herrera-Taracena, M. Van Loock, T. P. Endy, S. J. Thomas

This study analyzes the immune and virologic responses in humans infected with DENV-1, revealing new insights into the kinetics and composition of immune responses and gene modules involved in DENV infection.

bioRxiv · Feb 10, 2022Immunology

Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures

W. Chiu, L. Verschueren, C. Van den Eynde, C. Buyck, S. De Meyer, D. Jochmans, D. Bojkova, S. Ciesek, J. Cinatl, S. De Jonghe, P. Leyssen, J. Neyts, M. Van Loock, E. Van Damme

The paper develops a high-throughput screening assay to evaluate 5676 phase 1 compounds for in vitro anti-SARS-CoV-2 activity, identifying eight candidates but finding only remdesivir suitable for further clinical development.

bioRxiv · Feb 2, 2022Immunology

In Vitro Activity of Itraconazole Against SARS-CoV-2

E. Van Damme, S. De Meyer, D. Bojkova, S. Ciesek, J. Cinatl, S. De Jonghe, D. Jochmans, P. Leyssen, C. Buyck, J. Neyts, M. Van Loock

This paper assesses the in vitro antiviral activity of itraconazole and its metabolite against SARS-CoV-2, finding EC50 values of 2.3 μM and 3.6 μM, respectively, and reports no clinical efficacy in hospitalized patients.

bioRxiv · Nov 13, 2020Pharmacology & Toxicology

Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery

F. Touret, C. Baronti, O. Goethals, M. Van Loock, X. De Lamballerie, G. Querat

This paper establishes a dengue virus panel representing all genotypes to aid in antiviral drug discovery, showing varying compound efficacies across genotypes.

bioRxiv · Feb 28, 2019Microbiology